Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg impressed by "exceptional" dealmaking at Diploma

(Sharecast News) - Berenberg has hiked its target price for controls, seals and life sciences equipment firm Diploma by 16%, saying there is "a lot to like" about this week's acquisition of US-based specialty fasteners business Peerless. The broker maintained a 'buy' rating and lifted its target price for the shares from 3,800p to 4,400p.

Diploma announced on Wednesday that it was spending £236m on Peerless, one of the largest independent value-added distributors of aerospace fasteners and a "strong strategic fit" for the company at an attractive valuation.

Berenberg called the acquisition an "exceptional piece of dealmaking by management". The broker said: "It addresses investor questions about the sustainability of margins, the ability to source increasingly larger, yet still attractive and financially sensible deals as the group continues to grow, and whether mid-single-digit organic growth is sustainable for Diploma."

The move also marks a further push into fast structural growth markets, Berenberg said, which could see organic growth trend up beyond 6% over time. "There is a lot to like, as evidenced by a c10% share price move on the day," it said.

"At the group's FY 2023 results in November, we outlined the building blocks for mid-teens annual returns, while pointing to the M&A firepower available. Peerless builds on, if not accelerates, that thinking and brings the group's last three-year track record of 18% EPS growth CAGR sharply into focus."

The stock, after a big jump the previous session, was down 0.6% at 3,726p by 1240 GMT on Thursday.

Share this article

Related Sharecast Articles

Oxford Biomedica confident as it moves away from vaccine era
(Sharecast News) - Cell and gene therapy contract development and manufacturing organisation (CDMO) Oxford Biomedica reported stability in its core business on Monday, with a small increase in full-year core revenue for 2023, despite a 36% decrease in total revenue to £89.5m.
N Brown chairman Ron McMillan to retire
(Sharecast News) - N Brown said on Monday that chairman Ron McMillan will be retiring and stepping down from the board with effect from 30 April for personal reasons.
McCarthy out, Adshead in as Ultimate Products chair
(Sharecast News) - Ultimate Products, the parent of homeware brands including Salter and Beldray, announced a change in its leadership on Monday, with James 'Jim' McCarthy deciding to step down as non-executive chair from 31 July.
Digital 9 to make additional revolving credit facility repayment
(Sharecast News) - Infrastructure company Digital 9 Infrastructure announced a significant step towards strengthening its financial position on Monday, with the receipt of a deferred consideration payment of $25m (£20m) related to the sale of the Verne Global group, as announced on 15 March.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.